For instance, a phase 1 study of nivolumab plus peptide vaccine in resected stage IIIC/IV melanoma patients demonstrated “statistically significant increases in melanoma antigen-specific CD8+ T-cell populations and decreases in PD-1 expressing T-cells with exposure to nivolumab and vaccine” [75]. The gene discussed is CD8A; the disease is melanoma.